Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Nuformix receives £500,000 milestone payment

The AIM-listed group will receive a further £2mln when it passes the next development landmark
Nuformix receives £500,000 milestone payment
The company re-purposes already-approved drugs

Nuformix PLC (LON:NFX) has passed a pre-clinical milestone for its cancer drug, NXP001, triggering a £500,000 milestone payment from partner Newsummit Biopharma.

The AIM-listed group will receive a further £2mln if it is able to demonstrate bioequivalence to a reference product. In layman’s terms, this means NXP001 must have the same pharmaceutical effect as the reference drug.

Nuformix uses cocrystal technology to re-engineer crystalline drugs. This helps unlock the therapeutic potential of already-approved small molecule treatments.

View full PROAC profile View Profile

Proactiveinvestors Timeline

Newswire
November 08 2018

Related Articles

Marketing and public relations
April 04 2018
"Our Beyond, MBooth and Publitek agencies have been stand-out performers, whilst we have achieved solid performances pretty much across the portfolio"
ipad
September 19 2018
“Cello Health is successfully building its early stage asset development advisory platform for biotech clients, as well as growing its core later stage and post-launch franchise with pharmaceutical clients”
Clint Eastwood
May 25 2018
The group’s first piece of original content, a documentary called Pandas, premiered on 24 March this year, to positive reviews.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use